Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · Lytico-Bodig Disease

Understanding Lytico-Bodig Disease

At a Glance

Lytico-Bodig disease is a rare, progressive disorder that can combine ALS-like muscle weakness with Parkinson-like movement problems, memory loss, and behavior changes. There is no known cure, so care focuses on symptoms, safety, swallowing and breathing support, and quality of life.

Lytico-Bodig disease is a rare and complex neurological condition that combines the symptoms of several different brain disorders into one. If you or your loved one has been diagnosed with this, or if you are exploring it as a possibility, you may feel overwhelmed by the range of symptoms. This condition, also known as ALS-Parkinsonism-Dementia Complex (ALS/PDC), is a neurodegenerative spectrum—meaning it can look different from person to person because it affects various parts of the brain and nervous system simultaneously [1][2].

A Tale of Two Names

The traditional names for this disease come from the Chamorro language of Guam, where the condition was first identified. It is often referred to as Lytico-Bodig because it typically presents in two ways, though many people experience a mix of both [2]:

  • Lytico: This term describes symptoms that look like Amyotrophic Lateral Sclerosis (ALS) or motor neuron disease. It primarily involves progressive muscle weakness, wasting, and paralysis [1].
  • Bodig: This term describes symptoms that resemble Parkinsonism and Dementia. It involves stiffness, tremors, slow movement, and a decline in memory, judgment, and behavior [3][4].

The Mystery of the Disappearing Disease

Historically, Lytico-Bodig was a major health crisis on the island of Guam. In the mid-20th century, it reached hyperendemic levels, meaning it was extremely common among the Chamorro people—at one point, it was a leading cause of death for adults on the island [1][5].

Since that peak in the 1940s and 50s, the number of cases has declined dramatically. Today, experts call it a “disappearing disease” [6]. While the exact cause remains unproven, many researchers believe it was linked to environmental factors, such as toxins found in cycad seeds (used in traditional foods like fadang) or the fruit bats that ate those seeds [2][7]. As lifestyles and diets on the island changed, the incidence of the disease dropped.

Why Your Local Doctor May Be Unfamiliar

Because Lytico-Bodig is now so rare and was once geographically clustered in specific parts of the Western Pacific (Guam, Japan’s Kii Peninsula, and West Papua), many modern doctors—especially those outside these regions—have never seen a case [8].

Furthermore, because the disease can look so much like more common conditions—such as standard Parkinson’s, ALS, or Alzheimer’s—it is often misdiagnosed or simply called “ALS with dementia” [9][10]. If you or your loved one has a connection to Guam or these other regions, your observations are a vital part of the medical record, even if your doctor is learning about the condition alongside you.

Facing the Caregiving Reality

Caring for someone with Lytico-Bodig is uniquely challenging because it affects both physical and cognitive function at the same time. You are not just managing physical disability or memory loss; you are often managing both simultaneously [11].

  • Physical Decline: As the disease progresses, patients may lose the ability to walk, speak, or swallow. This eventually leads to a need for physical care and assistance with breathing [1][12].
  • Cognitive and Behavioral Changes: Unlike some other physical diseases, the “Bodig” aspect can cause profound changes in personality, memory, and judgment. (However, note that sudden cognitive or behavioral changes can also arise from treatable conditions like infections or medication side effects). This can make it harder for the patient to cooperate with the very physical help or equipment they need for safety [13][14].
  • Progressive: It is important to have honest conversations early. Lytico-Bodig is a progressive disease with no known cure or treatment that can stop its course [15][10]. While certain medications like levodopa (used for Parkinson’s) may temporarily help with stiffness, they do not stop the underlying decline [16]. However, active symptomatic treatment remains important.

The emotional weight of this diagnosis is significant. Caregivers often face a unique form of “anticipatory grief” as they watch their loved one navigate these changes [14]. Seeking a care team that includes specialists in both movement disorders and palliative care can help you focus on comfort and well-being throughout this journey [16][17].

Common questions in this guide

What is Lytico-Bodig disease?
Lytico-Bodig disease is a rare, progressive disorder of the brain and nervous system that can combine ALS-like muscle weakness with Parkinsonism, memory problems, and changes in judgment or behavior. It is also called ALS-Parkinsonism-Dementia Complex or ALS/PDC, and people may have different combinations of symptoms.
What symptoms can occur with Lytico-Bodig disease?
Symptoms may include muscle weakness, wasting, stiffness, tremors, and slowed movement, along with memory, judgment, or behavior changes. As the disease progresses, a person may have difficulty walking, speaking, swallowing, or breathing.
What might cause Lytico-Bodig disease?
The exact cause of Lytico-Bodig disease has not been proven. Researchers have investigated possible environmental exposures, including toxins associated with cycad seeds and fruit bats, and the condition historically clustered in Guam, Japan's Kii Peninsula, and West Papua.
Why can Lytico-Bodig disease be mistaken for another condition?
The disease is rare today and can resemble ALS, Parkinson's disease, or Alzheimer's disease, so it may be diagnosed as one of those conditions or as ALS with dementia. A history of living in or having a close connection to Guam, the Kii Peninsula of Japan, or West Papua can be important information for the medical team.
Can Lytico-Bodig disease be cured or stopped?
There is no known cure or treatment that stops the disease from progressing. Levodopa may temporarily improve stiffness in some people, while symptom-focused care, safety equipment, and palliative care can support comfort, swallowing, breathing, and quality of life.
What kind of care is needed as Lytico-Bodig disease progresses?
Care may need to address muscle weakness and cognitive or behavior changes at the same time. The care team can monitor walking, communication, swallowing, and breathing; plan home safety; and involve movement-disorder, motor-neuron-disease, and palliative-care specialists.
Could a sudden change in thinking or behavior have a treatable cause?
Yes. A sudden change in thinking or behavior may result from a treatable problem, such as an infection or a medication side effect, rather than only from Lytico-Bodig disease. Report sudden changes promptly to the person's healthcare team so they can be assessed.

Get notified when new evidence is published on Parkinson-dementia complex of Guam.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Lytico-bodig in Guam: Historical links between diet and illness during and after Spanish colonization.

    Giménez-Roldán S, Steele JC, Palmer VS, Spencer PS

    Journal of the history of the neurosciences 2021; (30(4)):335-374 doi:10.1080/0964704X.2021.1885946.

    PMID: 34197260
  2. 2

    Parkinsonism and motor neuron disorders: Lessons from Western Pacific ALS/PDC.

    Spencer PS

    Journal of the neurological sciences 2022; (433()):120021 doi:10.1016/j.jns.2021.120021.

    PMID: 34635325
  3. 3

    Dysfunction of Protein Quality Control in Parkinsonism-Dementia Complex of Guam.

    Verheijen BM, Oyanagi K, van Leeuwen FW

    Frontiers in neurology 2018; (9()):173 doi:10.3389/fneur.2018.00173.

    PMID: 29615966
  4. 4

    Cerebrovascular inflammation is associated with tau pathology in Guam parkinsonism dementia.

    Majerova P, Garruto RM, Kovac A

    Journal of neural transmission (Vienna, Austria : 1996) 2018; (125(7)):1013-1025 doi:10.1007/s00702-018-1883-3.

    PMID: 29700607
  5. 5

    Seeking environmental causes of neurodegenerative disease and envisioning primary prevention.

    Spencer PS, Palmer VS, Kisby GE

    Neurotoxicology 2016; (56()):269-283 doi:10.1016/j.neuro.2016.03.017.

    PMID: 27050202
  6. 6

    Brain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin.

    Spencer PS, Berntsson SG, Buguet A, et al.

    Journal of the neurological sciences 2025; (468()):123340 doi:10.1016/j.jns.2024.123340.

    PMID: 39667295
  7. 7

    Western Pacific ALS-PDC: Evidence implicating cycad genotoxins.

    Spencer PS, Palmer VS, Kisby GE

    Journal of the neurological sciences 2020; (419()):117185 doi:10.1016/j.jns.2020.117185.

    PMID: 33190068
  8. 8

    Kampō medicine and Muro disease (Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex): Postscript and Historical Footnote.

    Spencer PS, Palmer VS, Kihira T, et al.

    eNeurologicalSci 2021; (22()):100308 doi:10.1016/j.ensci.2020.100308.

    PMID: 33426315
  9. 9

    [Sporadic form of Guam disease (ALS-parkinsonism-dementia complex)].

    Kicherova OA, Doyan YI, Kicherova KP, et al.

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2025; (125(7)):135-141 doi:10.17116/jnevro2025125071135.

    PMID: 40760897
  10. 10

    [Parkinson-dementia and amyotrophic lateral sclerosis association (complex of Guam). Diagnostic challenge, Mexican patient].

    Aguilar-Vázquez CA, Gallardo-González LI, Raymundo-Carrillo AD, et al.

    Revista medica del Instituto Mexicano del Seguro Social 2023; (61(5)):677-684 doi:10.5281/zenodo.8316479.

    PMID: 37773166
  11. 11

    The frontotemporal dementia-motor neuron disease continuum.

    Burrell JR, Halliday GM, Kril JJ, et al.

    Lancet (London, England) 2016; (388(10047)):919-31.

    PMID: 26987909
  12. 12

    Providing life-sustaining treatments at home for those with Motor Neurone Disease: A qualitative study of bereaved family members' experiences of responsibility.

    Wilson E, Palmer J, Kaltsakas G, et al.

    Palliative medicine 2025; (39(5)):584-593 doi:10.1177/02692163251327866.

    PMID: 40119769
  13. 13

    The experiences of patients with amyotrophic lateral sclerosis of their decision-making processes to invasive home mechanical ventilation-A qualitative study.

    Thorborg T, Finderup J, Winther DS, et al.

    Nursing open 2023; (10(8)):5139-5148 doi:10.1002/nop2.1749.

    PMID: 37071691
  14. 14

    Exploring the experiences of living with Lewy body dementia: An integrative review.

    Bentley A, Morgan T, Salifu Y, Walshe C

    Journal of advanced nursing 2021; (77(12)):4632-4645 doi:10.1111/jan.14932.

    PMID: 34146346
  15. 15

    Activation of the Unfolded Protein Response and Proteostasis Disturbance in Parkinsonism-Dementia of Guam.

    Verheijen BM, Lussier C, Müller-Hübers C, et al.

    Journal of neuropathology and experimental neurology 2020; (79(1)):34-45 doi:10.1093/jnen/nlz110.

    PMID: 31750913
  16. 16

    Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.

    Quinn C, Elman L

    Continuum (Minneapolis, Minn.) 2020; (26(5)):1323-1347 doi:10.1212/CON.0000000000000911.

    PMID: 33003004
  17. 17

    Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.

    Oh J, Kim JA

    Journal of clinical nursing 2017; (26(23-24)):4129-4152 doi:10.1111/jocn.13945.

    PMID: 28681543

This page is for informational purposes only and does not constitute medical advice. A neurologist and the patient's care team should guide diagnosis, symptom treatment, safety planning, and breathing or swallowing support for each person.